Form 4: Daxor Corp Director Joy S. Goudie Acquires Stock Options

Director Joy S. Goudie reports acquisition of Daxor Corp stock options, contingent on SEC approval of plan amendment.

Summary

• On July 15, 2024, Joy S. Goudie, a director of Daxor Corp, acquired 2,500 stock options.
• The exercise price of these options is $9.20.
• The options vest in three installments: 833 on July 15, 2024, 833 on July 15, 2025, and 834 on July 15, 2026.
• The expiration date for these options is July 15, 2029.
• The grant of these options is contingent upon SEC approval to amend the Daxor Corporation 2020 Incentive Compensation Plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The grant of stock options to a director suggests confidence in the company's future, but the contingency on SEC approval introduces some uncertainty.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Risks

• The grant of the stock options is contingent on SEC approval of the amendment to the Daxor Corporation 2020 Incentive Compensation Plan; failure to obtain this approval would nullify the grant.

Industry Context

Stock option grants are a common form of executive compensation used to align the interests of management with those of shareholders.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign of alignment between management and shareholder interests.

Next Steps

• Daxor Corp needs to obtain SEC approval for the amendment to the 2020 Incentive Compensation Plan.

Key Dates